Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Donors with CM will be solicited from a waiting list of patients awaiting BMT from the waiting list of MUD searches.
Maximally matched donor will be searched for each eligible CML patient with a goal in mind to find other patients with CML that share both class I and class II determinants. Sharing of one class I II will be considered eligible for participation in the study. Peripheral blood and PBMC from the donors will be isolated, washed and irradiated.
The cells will be injected into the consenting patients intracutaneously at 2 weeks intervals for a total of 6 injections.
|Chronic Myeloid Leukemia||Biological: Allogeneic tumor cell vaccine||Phase 1 Phase 2|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00162513
|Hadassah Medical Organization|
|Jerusalem, Israel, 91120|
|Principal Investigator:||Shimon Slavin, MD||Hadassah Medical Organization|